Warning: The NCBI web site requires JavaScript to function. more...
Toward a treaty on safety and cost-effectiveness of pharmaceuticals and medical devices: enhancing an endangered global public good.
Faunce TA.
Global Health. 2006 Mar 28;2:5.
Related citations
Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy.
Faunce T, Doran E, Henry D, Drahos P, Searles A, Pekarsky B, Neville W.
Global Health. 2005 Oct 6;1:15.
KSR v. Teleflex. Part 2: Impact of U.S Supreme Court Patent Law on Canadian and global systems-based innovation ecologies.
Bouchard RA.
Health Law J. 2007;15:247-94.
Comparing patient access to pharmaceuticals in the UK and US.
Cohen J, Cairns C, Paquette C, Faden L.
Appl Health Econ Health Policy. 2006;5(3):177-87.
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal.
Aust New Zealand Health Policy. 2007 Jun 1;4:9.
Expert consensus (SBC/SBHCI) on the use of drug-eluting stents: recommendations of the Brazilian society of interventional cardiology/ Brazilian society of cardiology for the Brazilian public single healthcare system.
Lima VC, Mattos LA, Caramori PR, Perin MA, Mangione JA, Machado BM, Coelho WM, Bueno RR.
Arq Bras Cardiol. 2006 Oct;87(4):e162-7. Review. English, Portuguese.
[Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
Führlinger S.
Wien Med Wochenschr. 2006 Dec;156(23-24):612-8. German.
Medical management of the traumatic consequences of civil unrest incidents: causation, clinical approaches, needs and advanced planning criteria.
Ballantyne B.
Toxicol Rev. 2006;25(3):155-97. Review.
The FDA process for the evaluation and approval of orthopaedic devices.
Kirkpatrick JS, Stevens T.
J Am Acad Orthop Surg. 2008 May;16(5):260-7. Review.
Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P.
Value Health. 2007 Sep-Oct;10(5):336-47.
Toxicological and public good considerations for the regulation of nanomaterial-containing medical products.
Expert Opin Drug Saf. 2008 Mar;7(2):103-6.
Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy.
Nsimba SE.
East Afr J Public Health. 2008 Dec;5(3):205-10. Review.
The US drug safety system: role of the pharmaceutical industry.
Gibson BR, Suh R, Tilson H.
Pharmacoepidemiol Drug Saf. 2008 Feb;17(2):110-4.
Information on cost-effectiveness: an essential product of a national comparative effectiveness program.
American College of Physicians.
Ann Intern Med. 2008 Jun 17;148(12):956-61. Epub 2008 May 15.
Nanotherapeutics: new challenges for safety and cost-effectiveness regulation in Australia.
Med J Aust. 2007 Feb 19;186(4):189-91.
Standards for humidification and filtration devices.
Stevens J.
Respir Care Clin N Am. 2006 Jun;12(2):203-32. Review.
Economic implications of potential changes to regulatory and reimbursement policies for medical devices.
Reed SD, Shea AM, Schulman KA.
J Gen Intern Med. 2008 Jan;23 Suppl 1:50-6.
Researching safety and cost-effectiveness in the life cycle of nanomedicine.
Faunce T, Shats K.
J Law Med. 2007 Aug;15(1):128-35.
TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines?
Kerry VB, Lee K.
Global Health. 2007 May 24;3:3.
Medical devices and pharmaceuticals: differences in public acceptance.
Holmes DR Jr, Wood DL.
Am Heart Hosp J. 2006 Fall;4(4):269-72. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on